Monthly Health Review | June 2026: Yifeng Capital Portfolio Achieves Milestones in Funding, Clinical Breakthroughs, and Regulatory Approvals

On June 10, 2026, a new investment vehicle quietly registered in Shenzhen. The Yifeng Mingyuan Seed Fund, backed by the Shenzhen Technology Innovation Seed Fund, marked Yifeng Capital's boldest move yet into early-stage investing.

But the real story lies elsewhere. Throughout June, Yifeng's portfolio companies have been firing on all cylinders—closing funding rounds, launching clinical trials, and securing regulatory approvals at a pace that suggests the firm's investment thesis is finally paying off.

Funding Rounds Accelerate

Westlake Bio completed a strategic financing round exceeding 100 million yuan (approximately $14 million USD), with Yifeng Capital increasing its stake as a returning investor.

CarbonScape closed its Series A round, backed by Yifeng Capital and Boyuan Capital among others.

Barty Medical raised nearly 200 million yuan (approximately $28 million USD) in Series D funding to accelerate commercialization of its vascular intervention devices globally.

Vivolight secured several hundred million yuan in new financing, co-led by Sino-US Green Yangtze River Delta and Yifeng Capital.

Highlightll Pharma filed for an IPO on the Hong Kong Stock Exchange on June 8, marking another milestone for the portfolio.

Wuhan Ruijiakang obtained Series B funding from Yifeng Zhuohua Fund, earmarked for a 10,000-ton bio-based platform compound demonstration facility.

Clinical Breakthroughs and Regulatory Wins

Highlightll Pharma's JAK1/TYK2 inhibitor TLL-018 was nominated for Breakthrough Therapy Designation on June 24 for treating rheumatoid arthritis.

Trinomab partnered with Shanghai Pharmaceuticals Holding Co., Ltd (SPH) on June 23 to commercialize its tetanus antibody drug in the Philippines.

Atom Therapeutics launched Phase 3 clinical trials in China for its anti-gout drug ABP-671 (lingdolinurad) on June 23, with the first patient already enrolled and dosed.

Kening Bio initiated first-in-human clinical trials for its dry eye treatment, with the first subject receiving the drug.

Tianqin Bio showcased its non-human primate metabolic disease model at the 86th American Diabetes Association (ADA) Scientific Sessions in New Orleans.

Hannuo Medical demonstrated its Lifemotion ECMO system at the 8th Asia-Pacific Extracorporeal Life Support Organization Conference in Japan from June 11-13.

New Drugs and Devices Hit the Market

Pulai Pharma's PuYiKe®, China's first gram-negative antibacterial peptide Class 1 innovative drug, received NMPA approval on June 17.

Ruijing Bio's NGS thyroid cancer molecular detection kit—covering BRAF/TERT/RET/NTRK3 gene mutations—was approved by NMPA on June 23 as the first and only such test on China's NGS platform.

Huahao Zhongtian's oral solid microtubule stabilizer UTD2 (treating HER2-negative advanced breast cancer) received Phase 3 clinical trial approval from NMPA on June 11.

Vivolight's subsidiary Zhongke Rongguang obtained NMPA approval for its FastErazer triple-frequency Nd:YAG laser ablation device, featuring 355nm cold laser technology.

Tingsheng Tech's TINGSN Sonic Eyes 8 Pro intracardiac echocardiography catheter received NMPA Class III medical device registration on June 23—the company's seventh ICE product.

Xuanyu Medical's StrenSoft™ adjustable pulmonary artery thrombectomy stent system was approved by NMPA on June 1.

Sinobiologics' icaritin injection, a fully human BCMA-targeted CAR-T cell therapy, received marketing approval from Singapore's Health Sciences Authority (HSA) on June 18.

Industry Recognition

Century Kangtai established a postdoctoral research workstation sub-station.

Maijing Gene won the 2026 Global Medical Technology "Ophthalmology Innovation Device Award" and achieved perfect scores in the National Center for Clinical Laboratories' external quality assessment for solid tumor fusion gene NGS detection.

Yafeng Capital was recognized by 36Kr as a leading venture capital firm in China's equity investment industry. CEO Zhu Pai was named one of the "2026 China's Best Young Investors" by Anyong Waves.

The Bigger Picture

The June surge reflects a broader trend: China's biotech sector is moving from R&D-heavy pipelines to commercial execution. Portfolio companies are not just raising money—they're launching products, winning approvals, and expanding internationally.

For Yifeng Capital, the seed fund launch signals a strategic shift toward earlier-stage investments. But the real validation comes from the portfolio's performance. With multiple companies closing rounds, advancing through clinical trials, and securing regulatory approvals in a single month, the firm's thesis appears to be working.

The question now is whether this momentum can be sustained—or if June 2026 represents a peak rather than a trend.